相关实验视频

Updated: Jan 17, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

评估组合疗法与单独化疗在不可切除的原发性肺扩散性大B细胞淋巴瘤中的疗效:一项回顾性队列研究

Yuchen Liu¹, Ruonan An¹, Ping Cheng¹

¹School of Medicine, Nankai University, Tianjin, China.

Translational cancer research

|September 15, 2025

概括

综合疗法 (CMT) 显示,对于不可切除的原发性肺扩散性大B细胞淋巴瘤 (PP-DLBCL) 的生存率有所改善. 这项研究确定了关键的预后因素,有助于管理这种罕见的癌症.

科学领域:

在瘤学瘤学.
血液学血液学血液学
临床研究临床研究

背景情况:

原发性肺扩散性大B细胞淋巴瘤 (PP-DLBCL) 是一种罕见的,侵袭性的淋巴瘤.
无法切除的PP-DLBCL的最佳治疗策略仍然不清楚,特别是关于将放射治疗 (RT) 添加到化疗 (CT) 的好处.

研究的目的:

为了比较组合疗法 (CMT) 和单独CT之间的生存结果,在不能切割的PP-DLBCL患者中.
通过使用现实世界的数据,评估用于不可切割的PP-DLBCL的CT添加RT的疗效.

主要方法:

从SEER数据库 (2000-2021) 中提取了880名无法切除的PP-DLBCL患者的数据.
使用倾向分数匹配 (PSM) 来调整混因素.
使用Kaplan-Meier方法和Cox回归模型分析了整体生存率 (OS) 和癌症特异性生存率 (CSS).

主要成果:

与单独化学疗法 (CT) 相比,联合疗法 (CMT) 与明显改善的整体存活率 (OS) 相关 (HR,0.77;95% CI:0.59-0.99).
这种关联在倾向性得分匹配后保持一致.
对OS的独立预后因素包括性别,年龄和Ann Arbor阶段.

结论:

结合方式治疗 (CMT) 可能会提高无法切除的原发性肺扩散性大B细胞淋巴瘤 (PP-DLBCL) 患者的生存率.
确定预后因素可以帮助分层高风险患者.
这些发现为这种罕见淋巴瘤的临床治疗提供了有价值的证据.

关键词:

主要的肺扩散性大B细胞淋巴瘤 (PP-DLBCL)化学疗法 (CT) 的使用组合方式治疗 (CMT)预后因素预后因素放射疗法 (RT) 是一种疗法.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...